Gout: Treat-to-Target

Treat to target in gout

Source (Ref) Target sUA < 0.36 mmol/lLoE/ GoR/SoR Target sUA < 0.3 mmol/lLoE/ GoR/SoR
EULAR 2006 [21] 3/-/9.1 NE
BSR 2007 [22] -/C/-
ACR 2012 [23] -/A/- -/B/-
3E initiative 2014 [24] 2b/C/9.0 2b/B/9.2
EULAR 2016 [25] a 3/C/8.8
T2T 2016 [18] 1a/A/9.5 5/D/9.2
ACP 2016 [19, 20] Inconclusiveb Inconclusive
BSR 2017 [26] 4/-/9.7 3/-/9.7
aBoth targets evaluated altogether. bInconclusive evidence that escalating therapy to target and monitoring sUA has any benefit outweighing risk of adverse events. BSR: British Society for Rheumatology; ACP: American College of Physicians; LoE: level of evidence 1 (best) to 5, based on literature search; GoR: grade of recommendation A (best) to D, based on level of evidence; SoR: strength of recommendation based on panel voting 10 (best) to 0; NE: not evaluated.
Abstract. The treat-to-target (T2T) approach has been successfully…

T2T Improves Primary Care Gout Management

Researchers from Geisinger Medical center tested a pilot primary care gout management improvement intervention, and demonstrated…



Both high and low uric acid levels tied to higher mortality

(HealthDay)—Both high and low uric acid levels are associated with an…

To retrospectively analyze the efficacy and safety of febuxostat on gout patients with low serum…


The goal of urate lowering treatment is not merely a serum target, which is but the means to the end. The goal is to deplete the total tophaceous load, thereby reducing and eliminating arthritic flares eventually; and hopefully, to mitigate the reno-cardiovascular risks, reversing early damage if possible.

To assess the goals of gout treatment from a patient perspective, a convenience sample of consecutive patients with doctor-diagnosed gout…